Congenital Hypothyroidism
23
4
5
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.3%
1 terminated out of 23 trials
90.0%
+3.4% vs benchmark
9%
2 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (23)
Early Check: Expanded Screening in Newborns
Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)
Evaluation of an Intensified Systematic Screening for Congenital Hypothyroidism in Premature Newborns
Ultrasound Measurement of Thyroid Volume in Term Newborns
Role of Next Generation Sequencing in the Etiological Diagnosis of Permanent Congenital Hypothyroidism With in Situ Thyroid
Comparison of Levothyroxine Formulations in the Treatment of Congenital Hypothyroidism
Infants With Primary Congenital Hypothyroidism and Development
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.
Prospective Evaluation of OptiThyDose
Metabolic Risk Assessment in Prepubertal Children With Congenital Hypothyroidism
Baby Detect : Genomic Newborn Screening
Quality of Life and Long-term Outcome of Adequately Treated Congenital Hypothyroidism
Influence of Initial Levothyroxine Dose on Neurodevelopmental and Growth Outcomes in Congenital Hypothyroidism
Final Height in Patients With CH Diagnosed by the Screening
Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.
Generic vs. Name-Brand Levothyroxine
A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication
Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System